Albany Med and NYOH to Host Translational Oncology Symposium
ALBANY, N.Y., Aug. 28, 2013 — The 7th Annual Translational Oncology Research Symposium, “Transforming Basic Science Into Clinical Practice,” will be held at the Hilton Garden Inn Albany Medical Center Oct. 3-4.
This 1.5-day CME-certified conference will partner local and national experts in clinical oncology and basic cancer research to enhance understanding and collaboration between these groups and foster translational oncology in the Capital and Adirondack regions of New York.
The conference’s focus is on identifying practical recommendations to implement scientific findings into clinical practice, and supporting cancer research that has as its ultimate goal improved patient care.
The symposium is hosted by Albany Medical College and New York Oncology Hematology, P.C. (NYOH), and is jointly sponsored by the Medical College of Wisconsin. Attendees can earn
AMA PRA Category 1 Credits ™ by participating in this continuing medical educational activity.
Vincent Verdile, M.D., dean of Albany Medical College and executive vice president for health affairs at Albany Medical Center, will be a symposium moderator. “We are proud to offer this unique opportunity to bring together leading physicians and researchers in the field of oncology,” he said. “It is our hope that the fruitful discussions that occur among these experts will lead to innovative treatments and better outcomes for our patients.”
The symposium is co-chaired by Paul Higgins, Ph.D., and Paula McKeown-Longo, Ph.D., co-directors of Albany Med’s Center for Cell Biology and Cancer Research, and Karen Tedesco, M.D., director of the NYOH Hereditary Cancer Risk Assessment Program.
Among the highlights will be discussion of how breakthroughs in diagnostic and predictive tools are paving the way for the individualization of cancer treatment.
“The advent of personalized oncology has fostered a ‘next generation of pathology’ focused on predictive biomarkers,’’ said Jeffrey S. Ross, M.D., chairman of Albany Med’s Department of Pathology and Laboratory Medicine and a keynote address speaker. “This year’s Translational Oncology Symposium is replete with descriptions of genomic markers that predict both benefit and resistance for both conventional and modern targeted therapies for cancer.”
Lawrence Garbo, M.D., chairman of the NYOH Research Committee, will make opening and closing remarks Friday. The diverse group of oncology experts includes three keynote speakers: Dr. Ross; David M. Jablons, M.D., an Albany Medical College graduate and chief of Thoracic Surgery at the University of California, San Francisco Medical Center, and Lajos Pusztai M.D., D.Phil., co-director of the Cancer Genetics Research at Yale Medical Center.
There is no fee for this educational activity. For more information or to register, visit www.TransOncNY.org.
Statistical information presented in press releases may no longer be valid.